{"name": "NexBio",
 "permalink": "nexbio",
 "crunchbase_url": "http://www.crunchbase.com/company/nexbio",
 "homepage_url": "",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2002,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "858-452-2631",
 "description": "",
 "created_at": "Fri May 31 03:26:37 UTC 2013",
 "updated_at": "Fri May 31 03:31:19 UTC 2013",
 "overview": "\u003Cp\u003ENexBio is a San Diego based company in operation since 2003. NexBio is the recipient of five NIH grants totaling $14M and a BAA contract for $49.5M. NexBio\u2019s lead product, Fludase\u00ae, is currently undergoing Phase II clinical development. Fludase\u00ae is in clinical development as a first-in-class broad-spectrum prophylactic and therapeutic agent for Influenza-Like Illness caused by all annual and pandemic variations of influenza virus (IFV), including Pandemic Influenza A(H1N1) and avian H5N1, as well as parainfluenza. Fludase\u00ae is currently undergoing a Phase II clinical trial for the treatment of community acquired influenza. NexBio is performing lead optimization of a second novel protein therapeutic, Sepcidin\u2122. NexBio has also invented TOSAP\u00ae a proprietary microparticle formulation technology used for its compounds, as well as those of its partners. Our mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening human diseases.\u003C/p\u003E",
 "image": null,
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$5M",
 "funding_rounds":
  [{"round_code": "partial",
    "source_url": "http://www.sec.gov/Archives/edgar/data/1534671/000153467113000003/xslFormDX01/primary_doc.xml",
    "source_description": "SEC",
    "raised_amount": 5000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 5,
    "funded_day": 29,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "3030 CALLAN ROAD",
    "address2": "SUITE 200",
    "zip_code": "92121",
    "city": "SAN DIEGO",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": 32.90702,
    "longitude": -117.240486}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}